Season 4 of Surfing The NASH Tsunami

S4-38.4 - On the Capabilities of The Health Care Systems

S4-38.4 – On the Capabilities of The Health Care Systems

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.

S4-38.3 - Getting the Right Message to the Right Patient at the Right Time

S4-38.3 – Getting the Right Message to the Right Patient at the Right Time

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment features ideas around how health care systems can improve and important lessons learned from the COVID pandemic.

S4-38.2 - On the Importance of Multidisciplinary Teams

S4-38.2 – On the Importance of Multidisciplinary Teams

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment focuses on the importance of team work and the strengths that multidisciplinary approaches can provide when supporting patients.

S4-38.1 - 3 Important Questions to Consider for Full Patient Support

S4-38.1 – 3 Important Questions to Consider for Full Patient Support

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment introduces three important questions that the group aims to answer throughout the wider episode.

S4-38 - Nurses Helping NASH Patients

S4-38 – Nurses Helping NASH Patients

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.

S4-37 - Focus on the Role of Allied Health and Strengthening NASH Education

S4-37 – Focus on the Role of Allied Health and Strengthening NASH Education

This week, Surfing NASH looks back at a Season 3 episode that remains particularly relevant in light of recent stories on new nomenclature and therapeutic developments for liver disease. An all-star panel of liver nurses and advanced nurse practitioners join Louise Campbell and Stephen Harrison to explore the myriad ways allied health experts can play a broader role in NASH education and patient management.

S4-36.5 - LOCATE-NAFLD: What’s Next and Practical Takeaways

S4-36.5 – LOCATE-NAFLD: What’s Next and Practical Takeaways

New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This final conversation addresses the importance of adequate training in order to optimize the potential of advancing technologies. For final questions, James shares what’s next for the project and the other panelists discuss takeaways from this discussion in terms of improving screening or cost effectiveness.

S4-36.4 - LOCATE-NAFLD: Funding and Generating Data

S4-36.4 – LOCATE-NAFLD: Funding and Generating Data

New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation focuses on questions around funding before moving on to consider the importance of generating and managing the best sets of data. As the conversation concludes, the group discusses concerns over consistency of scan reads and shares tips on how to get a more accurate measurement.

S4-36.3 - LOCATE-NAFLD: Cost Effectiveness and Implementation in Different Systems

S4-36.3 – LOCATE-NAFLD: Cost Effectiveness and Implementation in Different Systems

New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation focuses on details of the study design related to cost effectiveness, scalability and feasibility when looking to implement in other countries.

S4-36.2 - LOCATE-NAFLD: Study Design and Early Analysis

S4-36.2 – LOCATE-NAFLD: Study Design and Early Analysis

New guest, Prof. James O’Breine, joins Naim Alkhouri, Louise Campbell and Roger Green to discuss improving models for patient identification and risk stratification with the LOCATE-NAFLD project. This conversation features general comments and questions around the study design before James shares two interesting pieces of data from early analysis.

S4-36.1 - Meeting James O’Beirne and Introducing the LOCATE-NAFLD Study

S4-36.1 – Meeting James O’Beirne and Introducing the LOCATE-NAFLD Study

Naim Alkhouri, Louise Campbell and Roger Green introduce new guest Prof. James O’Beirne and his efforts in creating improved models for patient identification and risk stratification to the SurfingNASH community. This conversation features a crash course, both personal and professional, on James before diving into an overview of the LOCATE-NAFLD study.

S4-35.4 - Looking Forward at the SurfingNASH Program

S4-35.4 – Looking Forward at the SurfingNASH Program

The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation hones in on what the audience can expect and look forward to learn more about in the coming months.

S4-35.3 - Strengthening Patient Involvement, NIT Development and Lessons from AI

S4-35.3 – Strengthening Patient Involvement, NIT Development and Lessons from AI

The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation discusses the growing trend of patient involvement, the factors for and benefits of NIT development, lessons from artificial intelligence and more.

S4-35.2 - Challenges Associated with Communicating New Nomenclature

S4-35.2 – Challenges Associated with Communicating New Nomenclature

The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation focuses largely on the various challenges associate with adopting and communicating new nomenclature for liver disease.

S4-35.1 - High-Level Recap of Two Key Events for 2023 Thus Far

S4-35.1 – High-Level Recap of Two Key Events for 2023 Thus Far

The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation introduces two topics to expound on which standout amid a year that proves to be rife with rich, new information.

S4-34.6 - From the Vault: Presentation on Efruxifermin in NASH with Fibrosis

S4-34.6 – From the Vault: Presentation on Efruxifermin in NASH with Fibrosis

On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation From the Vault to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

S4-34.5 - GLP-1s and Lean Muscle Loss

S4-34.5 – GLP-1s and Lean Muscle Loss

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.

S4-34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

S4-34.4 – Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.

S4-34.3 - The Increasing Importance of Omics

S4-34.3 – The Increasing Importance of Omics

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation focuses on the increasing importance of omics and potentially powerful weight-loss therapies presented at the ADA meeting. Other major themes in this session include insights on the role of artificial intelligence and epigenetics.

S4-34.2 - Practical and Plausible Notes On Injectables Versus Oral Agents

S4-34.2 – Practical and Plausible Notes On Injectables Versus Oral Agents

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation digs deeper into the FASCINATE-2 interim analysis data at week 26 of the 52-week trial. The discussion develops into practical and plausible considerations in a comparison between injectable and oral agents.

S4-34 - Drug Development Stories from EASL and ADA: Part 2

S4-34 – Drug Development Stories from EASL and ADA: Part 2

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.

S4-33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-33.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

Last year, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). This conversation From the Vault revisits still relevant takeaways as the podcast continues its coverage of emerging stories from EASL Congress 2023.

S4-33.4 - More Presentation Insights on Frequency of Testing, NITs and Biopsy

S4-33.4 – More Presentation Insights on Frequency of Testing, NITs and Biopsy

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This final session focuses on another paper by Vincent Wong which sparks discussion around the plausibility of shifting from biopsy to NITs and the cost effectiveness and frequency of testing.

S4-33.3 - Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

S4-33.3 – Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This session focuses on a study aimed at connecting steatotic liver disease in patients without cirrhosis to HCC outcomes over a ten year period. After, the group unpacks how little is known about the mechanisms of fibrosis resolution.

S4-33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

S4-33.1 - EASL Congress 2023: Focus on New Nomenclature

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.

S4-33 - EASL Congress: Nomenclature and More Compelling Presentations

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.

S4-32.4 - The Potential of NASH Drugs as Adjuvant Therapy

S4-32.4 – The Potential of NASH Drugs as Adjuvant Therapy

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.

S4-32.3 - Discussing Other Drugs in the Therapeutic Landscape

S4-32.3 – Discussing Other Drugs in the Therapeutic Landscape

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group moves on from analysis around resmetirom to discuss other drug classes in the therapeutic landscape.

S4-32.2 - Why We Should Develop Deeper Understanding of Liver Volume

S4-32.2 – Why We Should Develop Deeper Understanding of Liver Volume

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group continues to unpack fresh data on resmetirom, discuss its safety profile and speculate ideas around how the field could benefit from an improved understanding of liver volume dynamics.

S4-32 - Drug Development Stories from EASL and ADA: Part 1

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

S4-31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

S4-31.4 – EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.

S4-31.1 - Mazen Noureddin on "NASH Monopoly"

S4-31.1 – Mazen Noureddin on “NASH Monopoly”

Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This is the first conversation of a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions.

S4-30.4 - EASL Congress 2023: Final Takeaways

S4-30.4 – EASL Congress 2023: Final Takeaways

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this final conversation the panelists revisit some of the more interesting moments of the meeting before answering a question around what takeaways will reshape the way we think and act moving forward.

S4-30.3 - EASL Congress 2023: More Posters and Presentations

S4-30.3 – EASL Congress 2023: More Posters and Presentations

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this conversation each panelist revisits the posters and presentations they found compelling. As expected from such a diverse group, the discussion touches on a range of fascinating topics all worth consideration.

S4-30.1 - EASL Congress 2023: Nomenclature Rollout

S4-30.1 – EASL Congress 2023: Nomenclature Rollout

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this first of four conversations, the panelists share their initial impressions before diving into the implications of the new nomenclature rollout.

S4-29.3 - EASL Congress 2023: Final Thoughts on Days 1-3

S4-29.3 – EASL Congress 2023: Final Thoughts on Days 1-3

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. This final conversation around days 1-3 explores the landscape of AI in the context of better understanding liver diseases. The group also discusses FGF-21 agents, NAIL-NIT data and more.

S4-29.2 - EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

S4-29.2 – EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group discusses a session that Jörn co-chaired on challenges in screening patients for fatty liver diseases. Notes touch on how time restrictions obstruct frontline treaters from offering both adequate screening and support lifestyle interventions simultaneously. The group goes on to consider the potential of dual agonists efinopegdutide and pemvidutide.

S4-E29.1 - EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results

S4-E29.1 – EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group shares their initial impressions of the first three days of the meeting. Notably, they explore Stephen Harrison’s presentation of the highly anticipated MAESTRO-NASH Phase 3 results.

S4-30 - EASL Congress 2023: Real-Time Review Part 2

S4-30 – EASL Congress 2023: Real-Time Review Part 2

Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. The panelists discuss nomenclature, basic scientific and therapeutic insights and much more.

S4-29 - EASL Congress 2023: Real-Time Review Part 1

S4-29 – EASL Congress 2023: Real-Time Review Part 1

Surfing NASH reports on-site coverage from EASL Congress 2023 in Vienna. Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green get together early in the morning to compare notes and takeaways from an energizing meeting.

S4-28 - Tetiana Deshko on the public health care in Ukraine during the invasion

S4-28 – Tetiana Deshko on the public health care in Ukraine during the invasion

For the first time, Surfing NASH will not be discussing liver disease on the podcast. Instead, Roger Green and Michael Betel host an exclusive interview with Tetiana Deshko, Director of Programs for the Alliance for Public Health in Ukraine. Dr Deshko shares her moving story of the challenges of providing health for patients in the midst of an invasion and the challenges public health advocates face in caring for these patients on the frontlines of a war.

S4-27.3 - Abstract session - NAFLD: Clinical Aspects

S4-27.3 – Abstract session – NAFLD: Clinical Aspects

This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.

S4-27.2 - Abstract session - NAFLD: Therapy

S4-27.2 – Abstract session – NAFLD: Therapy

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green continues to unpack the rich EASL Congress 2023 program by discussing abstracts and presentations of interest. The group dives deep into liver science with commentary around emerging developments in NAFLD/NASH therapeutics.

S4-27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg

S4-27.1 – Unpacking the Program with Ian Rowe and Jörn Schattenberg

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green begins to unpack the rich EASL Congress 2023 program and explore in detail presentations of interest. Specifically, the group dives into anticipations around an abstract session around diagnostics and non-invasive assessment.

S4-27 - EASL Congress 2023 Preview: Great Talks to Anticipate!

S4-27 – EASL Congress 2023 Preview: Great Talks to Anticipate!

This episode comprises three separate sessions as part of the Surfing NASH ongoing coverage of a highly anticipated EASL Congress 2023. The first two discussions feature Ian Rowe, Jörn Schattenberg, Louise Campbell and Roger Green as the group reviews their lists of abstracts to look forward to. Following is an extra-sode on the subject of AI and pathology with guests Arun Sanyal and David Kleiner.

S4-26.3 - FibroScan and the Impact of Socioeconomic Factors on Liver Health

S4-26.3 – FibroScan and the Impact of Socioeconomic Factors on Liver Health

The podcast celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. This conversation offers observations around the new NICE guidance that supports FibroScan use in primary care settings. The group ventures on to discuss the effects of socioeconomic status on access to improved liver health.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.